Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction

Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial

Published:2020-03 Issue: Volume:221 Page:39-47
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Tripolt Norbert J,Kolesnik Ewald,Pferschy Peter N,Verheyen Nicolas,Ablasser Klemens,Sailer Sandra,Alber Hannes,Berger Rudolf,Kaulfersch Carl,Leitner Katharina,Lichtenauer Michael,Mader Arthur,Moertl Deddo,Oulhaj Abderrahim,Reiter Christian,Rieder Thomas,Saely Christoph H.,Siller-Matula Jolanta,Weidinger Franz,Zechner Peter M,von Lewinski Dirk,Sourij Harald

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference22 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study;Kosiborod;Diabetes Obes Metab,2018

3. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target;Di Franco;Int J Cardiol,2017

4. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia;DeFronzo;Diabetes Obes Metab,2012

5. Understanding EMPA-REG OUTCOME;Ceriello;The Lancet Diabetes & Endocrinology,2015

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin;Scientific Reports;2024-07-02

2. Dapagliflozin in Post-Myocardial Infarction Acute Decompensated Heart Failure: Daffodil Study;Journal of the Practice of Cardiovascular Sciences;2024-05

3. Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial;Cardiovascular Diabetology;2024-04-27

4. Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review);Molecular Medicine Reports;2024-03-11

5. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial;Diabetes, Obesity and Metabolism;2024-01-29